AF/1600

DOCKET NO.: PHOE-0061

PATENT

JUL 2 9 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ROEMARY In Re Application of:

Charles Mark Ensor et al.

Application No.: 09/921,380

Filing Date: August 2, 2001

For: PEG-MODIFIED URICASE

Confirmation No.: 7237

Group Art Unit: 1652

Examiner: Charles L. Patterson, Jr.

EXPRESS MAIL LABEL NO: EV 325637825 US

DATE OF DEPOSIT: July 29, 2003

EV325637825US

Mail Stop

NON-FEE

AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REPLY TRANSMITTAL LETTER

	Transmitted herewith for filing in the above-identified patent application is:						
	A Preliminary Amendment.						
\boxtimes	An Amendment Responsive to the Office Action Dated April 29, 2003.						
	An Amendment Supplemental to the Paper filed .						
	Other: .						
\boxtimes	Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.						
	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:						
	an Independent Inventor						
	a Small Business Concern						

DO	CKET NO.: PHOE-0061 - 2 - PATENT							
	a Nonprofit Organization							
	This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.							
	Loss of Entitlement Enclosed							
	Substitute Pages of the Specification are enclosed.							
	An Abstract is enclosed.							
	Sheets of Proposed Corrected Drawings are enclosed.							
	A Certified Copy of each of the following applications: is enclosed.							
	An Associate Power of Attorney is enclosed.							
	Information Disclosure Statement.							
	Attached Form 1449.							
	A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.							
	Appended Material as follows:							
\boxtimes	Other Material as follows: Declaration of Mike A. Clark with Exhibit A - copy of application as filed, Exhibit B - copy of Pending Claims and Exhibit C - The Effect of the Molecular Weight of PEG on the Retention of Uricase Biological Activity by PEG-Uricase in vitro and its Circulating Half-Life in Mice.							

FEE CALCULATION

No Additional Fee is Due.

				SMALL ENTITY		NOT SMALL ENTITY			
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE FEE		
TOTAL CLAIMS INDEP.	29	56 (20 MINIMUM)	0	\$9 EACH	\$0	\$18 EACH	\$		
CLAIMS	3	5 (3 MINIMUM)	0	\$42 EACH	\$0	\$84 EACH	\$		
	ESENTATION OF M MONTH EXTENSION	\$140	\$0	\$280	\$				
1	\$55	\$0	\$110	\$					
TWO	\$205	\$0	\$410	\$					
1	☐ THREE MONTH EXTENSION OF TIME					\$930	\$		
FOUR	MONTH EXTENSIO	N OF TIME		\$725	\$0	\$1450	\$		
	MONTH EXTENSION	\$985	\$0	\$1970	\$				
LESS .	ANY EXTENSION FI	EE ALREADY I	PAID	minus	(\$0)	minus	(\$)		
☐ TERM	INAL DISCLAIMER		\$55	\$0	\$110	\$			
OTHE	R FEE OR SURCHAR		0		Ψ				
	TOTAL FEI		\$0	,	\$				
	A check in the amount of \$\) .00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050. Petition is hereby made under 37 CFR \{ \} 1.136(a) (fees: 37 CFR \{ \} 1.17(a)(1)-(4) to extend the time for response to the Office Action of to and through comprising an extension of the shortened statutory period of month(s).								
	The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.								
	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is provided in duplicate.								
	The foregoing amount due for filing this paper.								
	Any additional filing fees required, including fees for the presentation of extra claims under 37 CFR § 1.16.								

DOCKET NO.: PHOE-0061

- 4 -

PATENT

Any additional patent application processing fees under 37 CFR § 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: July 29, 2003

Jane E. Inglese, Ph.D. Registration No. 48,444

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2003 WW